Ocular Pharmacokinetics of Fluocinolone Acetonide Following Iluvien Implantation in the Vitreous Humor of Rabbits [PDF]
Journal of Ocular Pharmacology and Therapeutics, 2015 The purpose of this study was to evaluate the systemic and ocular pharmacokinetics (PK) of fluocinolone acetonide (FAc) following administration of Iluvien(®) intravitreal implants.The FAc intravitreal implant was administered to rabbits in 3 doses (0.2, 0.5, and 1.0 μg/day).
Frances E, Kane, Kenneth E, Green
openaire +2 more sources
Drug Design, Development and Therapy, 2023 Yusuf Mushtaq,1,* Maryam M Mushtaq,2,* Zisis Gatzioufas,3 Matteo Ripa,4 Lorenzo Motta,5 Georgios D Panos1 1Department of Ophthalmology, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust & School of Medicine, University of ...
Mushtaq Y +5 more
doaj
Treatment Strategies for Refractory Diabetic Macular Edema: Switching Anti-VEGF Treatments, adopting corticosteroid-based treatments, and combination therapy [PDF]
, 2016 Introduction: The pathophysiology of diabetic macular edema (DME) is complex, involving vascular endothelial growth factor (VEGF) and other inflammatory mediators.
Ciulla, Thomas A., Hussain, Rehan M.
core +1 more source
Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation [PDF]
, 2022 The long-term effect of intravitreal Fluocinolone acetonide (FAc) on retinal morphology and function in diabetic macular edema (DME) was investigated. Seventeen eyes of twelve consecutive DME patients, treated by intravitreal FAc, were retrospectively ...
Falsini, Benedetto (ORCID:0000-0002-3569-4968) +4 more
core +1 more source
Intravitreal ILUVIEN® Implant for Diabetic Macular Oedema – Early Case Experiences
European Ophthalmic Review, 2013 Diabetic macular oedema (DMO) is an important cause of vision loss and challenges remain in the treatment of this progressive disease. Corticosteroids provide a comprehensive treatment approach, lowering the concentration of inflammatory cytokines and growth factors such as vascular endothelial growth factor (VEGF). However, intravitreal injections are
Anke Messerschmidt-Roth +1 more
openaire +1 more source
Wirksamkeit und Sicherheitsprofil von Iluvien ® im klinischen Alltag
, 2016 Hintergrund: Iluvien® (Fluocinolon Acetonide) ist als second line Therapie seit 2013 bei chronischem DMÖ, das auf andere verfügbare Therapien unzureichend anspricht, zugelassen. Methoden: Retrospektive Fallserie aller seit 2013 in unserer Klinik mit Iluvien® behandelten Augen [zum vollständigen Text gelangen Sie über die oben angegebene URL]
Bendschneider, D, Wachtlin, J
openaire +2 more sources
Erratum: Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes [PDF]
Eye, 2016 Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised ...
A, Kumar +4 more
openaire +4 more sources
Scleral fixation of fluocinolone acetonide implant
American Journal of Ophthalmology Case Reports, 2020 Purpose: To report on the technique of scleral fixation of fluocinolone acetonide (FAc) implant in 2 eyes with recalcitrant diabetic macular edema (DME). Observations: Two eyes of 2 patients with persistent DME, partially responsive to anti-VEGF therapy,
Homayoun Tabandeh, Kourous Rezaei
doaj +1 more source
Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management [PDF]
, 2020 Purpose: To investigate baseline characteristics of patients undergoing additional antivascular endothelial growth factor (VEGF) injections for residual or recurrent diabetic macular edema (DME) in the first year after 0.19-mg fluocinolone acetonide (FAc)
Bandello F. +5 more
core +1 more source